Back

HRS-7249, a small interfering RNA targeting apolipoprotein C3, in healthy subjects

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Novel lipid‑lowering therapies for residual risk Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Bo Jiang

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (China)

6 More presentations in this session

Presentation thumbnail
Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trials
Doctor P. Corral (Mar del Plata, AR)
Abstract Slides
Presentation thumbnail
Adherence and legacy effects of high dose eicosapentaenoic acid in hypertriglyceridemia and high CV risk – REDUCE-IT Legacy
Professor C. Packard (Glasgow, GB)
Abstract Slides
Presentation thumbnail
Long term efficacy and adherence of inclisiran in real-world clinical practice: insights from the CHOLINET Registry
Doctor F. Marzano (Naples, IT)
Abstract Slides
Presentation thumbnail
Perceived effectiveness of PCSK9i-SiRNA therapy and adherence to background statin therapy: real-world analysis of the DAMAGE registry
Associate Professor F. Guerra (Ancona, IT)
Abstract Slides
Presentation thumbnail
Determinants of short term Lp(a) variability in phase 3 obicetrapib trials
Doctor J. Kastelein (Amsterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Novel lipid‑lowering therapies for residual risk

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency
31 August 2020
thumbnail
Congress Presentation
BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects
29 August 2025
thumbnail
Congress Session
New frontiers in heart failure therapies
19 May 2025
thumbnail
Congress Presentation
Effect and safety of PCSK9 inhibitor in-hospital use on blood lipid level in the ACS patients: a systematic review and meta-analysis
13 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources